These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37947758)

  • 21. Decreases in Suicidality Following Psychedelic Therapy: A Meta-Analysis of Individual Patient Data Across Clinical Trials.
    Zeifman RJ; Yu D; Singhal N; Wang G; Nayak SM; Weissman CR
    J Clin Psychiatry; 2022 Jan; 83(2):. PubMed ID: 35044730
    [No Abstract]   [Full Text] [Related]  

  • 22. The challenges ahead for psychedelic 'medicine'.
    Muthukumaraswamy S; Forsyth A; Sumner RL
    Aust N Z J Psychiatry; 2022 Nov; 56(11):1378-1383. PubMed ID: 35243919
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.
    Argento E; Socias ME; Hayashi K; Choi J; Mackay L; Christie D; Milloy MJ; DeBeck K
    Int J Drug Policy; 2022 Feb; 100():103518. PubMed ID: 34758431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials.
    Noorani T; Bedi G; Muthukumaraswamy S
    Psychol Med; 2023 Oct; 53(13):5892-5901. PubMed ID: 37466178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
    Simonsson O; Goldberg SB
    J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pro-coagulant haemostatic factors for the prevention and treatment of bleeding in people without haemophilia.
    Fabes J; Brunskill SJ; Curry N; Doree C; Stanworth SJ
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD010649. PubMed ID: 30582172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. E-Health interventions for anxiety and depression in children and adolescents with long-term physical conditions.
    Thabrew H; Stasiak K; Hetrick SE; Wong S; Huss JH; Merry SN
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012489. PubMed ID: 30110718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy.
    Luoma JB; Chwyl C; Bathje GJ; Davis AK; Lancelotta R
    J Psychoactive Drugs; 2020; 52(4):289-299. PubMed ID: 32529966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Importance of Integrating Spiritual, Existential, Religious, and Theological Components in Psychedelic-Assisted Therapies.
    Palitsky R; Kaplan DM; Peacock C; Zarrabi AJ; Maples-Keller JL; Grant GH; Dunlop BW; Raison CL
    JAMA Psychiatry; 2023 Jul; 80(7):743-749. PubMed ID: 37256584
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled trials of biomarker targets.
    Erlendsdottir M; Crawford FW
    Clin Trials; 2023 Feb; 20(1):47-58. PubMed ID: 36373783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.
    Szigeti B; Nutt D; Carhart-Harris R; Erritzoe D
    Sci Rep; 2023 Jul; 13(1):12107. PubMed ID: 37495637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adapting psychedelic medicine for headache and chronic pain disorders.
    Schindler EAD; Hendricks PS
    Expert Rev Neurother; 2023; 23(10):867-882. PubMed ID: 37652000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychedelics: Where we are now, why we got here, what we must do.
    Belouin SJ; Henningfield JE
    Neuropharmacology; 2018 Nov; 142():7-19. PubMed ID: 29476779
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychiatry & the psychedelic drugs. Past, present & future.
    Rucker JJH; Iliff J; Nutt DJ
    Neuropharmacology; 2018 Nov; 142():200-218. PubMed ID: 29284138
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.
    Anglemyer A; Horvath HT; Bero L
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):MR000034. PubMed ID: 24782322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ketamine and other glutamate receptor modulators for depression in adults.
    Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.